Nektar Therapeutics (NASDAQ:NKTR) Director R Scott Greer sold 10,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the sale, the director now owns 140,333 shares in the company, valued at $9,457,040.87. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Nektar Therapeutics stock opened at $65.00 on Friday. The stock has a market cap of $11.38 billion, a PE ratio of 13.31 and a beta of 2.27. Nektar Therapeutics has a fifty-two week low of $21.11 and a fifty-two week high of $111.36. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.11. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. Nektar Therapeutics’s revenue for the quarter was up 3043.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.39) EPS. research analysts expect that Nektar Therapeutics will post 3.77 EPS for the current fiscal year.
Several equities research analysts have issued reports on NKTR shares. Mizuho reiterated a “buy” rating and issued a $103.00 price target on shares of Nektar Therapeutics in a research note on Thursday, August 9th. Piper Jaffray Companies set a $125.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 25th. BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. HC Wainwright lowered shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating and set a $54.00 price target on the stock. in a research note on Monday, June 11th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Nektar Therapeutics from $90.00 to $78.00 and set an “overweight” rating on the stock in a research note on Monday, June 4th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Nektar Therapeutics currently has an average rating of “Buy” and a consensus target price of $82.91.
Several institutional investors have recently added to or reduced their stakes in the company. HRT Financial LLC acquired a new position in shares of Nektar Therapeutics during the 2nd quarter worth about $421,000. Advisors Asset Management Inc. acquired a new position in shares of Nektar Therapeutics during the 2nd quarter worth about $373,000. Public Employees Retirement System of Ohio acquired a new position in shares of Nektar Therapeutics during the 2nd quarter worth about $3,130,000. HighPoint Advisor Group LLC increased its stake in shares of Nektar Therapeutics by 66.4% during the 2nd quarter. HighPoint Advisor Group LLC now owns 11,335 shares of the biopharmaceutical company’s stock worth $680,000 after purchasing an additional 4,522 shares during the last quarter. Finally, WINTON GROUP Ltd increased its stake in shares of Nektar Therapeutics by 41.1% during the 2nd quarter. WINTON GROUP Ltd now owns 7,685 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 2,238 shares during the last quarter. Institutional investors own 92.56% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.